Cabergoline Use for Pituitary Tumors and Valvular Disorders

Auriemma, Renata S.; Pivonello, Rosario; Ferreri, Lucia; Priscitelli, Prisco; Colao, Annamaria

doi:10.1016/j.ecl.2014.10.007

Cited by 43 publications

(24 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…High dose DA (as offered in Parkinson's syndrome) increases the risk of cardiac valvulopathy [95] but the risk of clinically significant valvulopathy in patients with prolactinoma is still not clearly established [96]. Most studies on prolactinoma patients do not show an elevated risk [97][98][99] but, given the uncertainty around the risk of valvulopathy in this setting, current guidelines recommend screening echocardiography prior to initiating DA, and thereafter every five years for patients taking cabergoline less than 2 mg per week or annually for those on more than 2 mg per week [100].…”

Section: Dopamine Agonistsmentioning

confidence: 99%

Hyperprolactinaemia

Samperi

Lithgow

Karavitaki

2019

JCM

View full text Add to dashboard Cite

Hyperprolactinaemia is one of the most common problems in clinical endocrinology. It relates with various aetiologies (physiological, pharmacological, pathological), the clarification of which requires careful history taking and clinical assessment. Analytical issues (presence of macroprolactin or of the hook effect) need to be taken into account when interpreting the prolactin values. Medications and sellar/parasellar masses (prolactin secreting or acting through "stalk effect") are the most common causes of pathological hyperprolactinaemia. Hypogonadism and galactorrhoea are well-recognized manifestations of prolactin excess, although its implications on bone health, metabolism and immune system are also expanding. Treatment mainly aims at restoration and maintenance of normal gonadal function/fertility, and prevention of osteoporosis; further specific management strategies depend on the underlying cause. In this review, we provide an update on the diagnostic and management approaches for the patient with hyperprolactinaemia and on the current data looking at the impact of high prolactin on metabolism, cardiovascular and immune systems.

show abstract

Section: Dopamine Agonistsmentioning

confidence: 99%

Hyperprolactinaemia

Samperi

Lithgow

Karavitaki

2019

JCM

View full text Add to dashboard Cite

show abstract

“…• Mitigar las manifestaciones clínicas, mediante antagonistas dopaminérgicos como la cavergolina (0,5-6 mg/día) 19 o bromocriptina (1,25-2,5 mg/día), análogos de somatostatina como el ocreótido (300 µg/día subcutáneo) o lanreótido (30mg intramuscular cada 28 días); o bien antagonistas del receptor de GH como el pegvisomant (10-30 mg/día). Existen tratamientos especializados para pacientes embarazadas 20 y se han desarrollado nuevos medicamentos con diversos mecanismos de acción y mayor seguridad como el pasireotide 21 .…”

Section: Discussionunclassified

Recidiva de macroadenoma hipofisario posterior a tratamiento estándar

Méndez-Fandiño

Perez-Ángel

Quintero-Moreno

et al. 2017

revmed

View full text Add to dashboard Cite

“…Treatment with cabergoline has been associated with unusual short-term side effects related to tumour shrinkage, such as cerebrospinal fluid leakage, chiasmal herniation and pituitary apoplexy. However, the main concerns of cabergoline use are related to its cumulative dose and long-term potential cardiac effects 4 14 15. This drug has been associated with subclinical lesions, such as aortic calcifications and tricuspid regurgitation and periodic echocardiographic monitoring is recommended in these patients 3 15–17.…”

Section: Discussionmentioning

confidence: 99%

Ten-year follow-up of a giant prolactinoma

et al. 2015

View full text Add to dashboard Cite

SUMMARY Giant prolactinomas are rare pituitary tumours of which management can be a challenge. A 28-year-old man presented with headaches, visual impairment and behavioural changes. Clinically, the patient was found to have hypogonadism and bitemporal hemianopsia. A MRI demonstrated a pituitary tumour 76 mm in diameter and blood tests revealed a serum prolactin of 158 700 mU/mL (reference range 58-254). Initially, a craniotomy was performed. Immunohistochemistry of the tumour identified a prolactinoma with a high proliferative index and the patient was started on treatment with a dopamine agonist. A year later, neurological symptoms worsened due to regrowth of the lesion's cystic component, and so further surgery was performed. After 10 years of treatment with dopamine agonists, the prolactin levels decreased by 96.8%, there was an effective reduction in tumour size, and the neurological signs and symptoms resolved. BACKGROUND

show abstract

Cabergoline Use for Pituitary Tumors and Valvular Disorders

Cited by 43 publications

References 52 publications

Hyperprolactinaemia

Hyperprolactinaemia

Recidiva de macroadenoma hipofisario posterior a tratamiento estándar

Ten-year follow-up of a giant prolactinoma

Contact Info

Product

Resources

About